BioNTech confirmed the acquisition of CureVac in a $1.25 billion all-stock deal that resolves ongoing mRNA patent litigation while enhancing its oncology pipeline. The agreement includes CureVac’s research and manufacturing assets, and gives CureVac shareholders a 4–6% stake in BioNTech. This strategic move positions BioNTech to further advance mRNA cancer immunotherapies and maintain leadership in the field.